Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
Phase 2 Recruiting
140 enrolled
ASCENDE-SBRT
Phase 3 Recruiting
710 enrolled
EVOLVE-BDT
Phase 2 Recruiting
700 enrolled
VA STARPORT
Phase 2/3 Recruiting
464 enrolled
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Phase 2 Recruiting
125 enrolled
PRO-BOOST-LC
Phase 2/3 Recruiting
1,200 enrolled
PRO-BOOST-N
Phase 2/3 Recruiting
1,600 enrolled
HAYATE
Recruiting
100 enrolled
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
Phase 2 Recruiting
12 enrolled
EvoPAR-PR02
Phase 3 Recruiting
700 enrolled
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Phase 2 Recruiting
90 enrolled
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Phase NA Recruiting
60 enrolled
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Phase 2 Recruiting
200 enrolled
METRO
Phase NA Recruiting
118 enrolled
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
Phase 2 Recruiting
60 enrolled
Pembro With Radiation With or Without Olaparib
Phase 2 Recruiting
64 enrolled
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 Recruiting
118 enrolled
(RANGER)
Phase 2 Recruiting
68 enrolled
Apa/Enza-short
Phase 3 Recruiting
400 enrolled
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Phase 2/3 Recruiting
83 enrolled
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Phase 2 Recruiting
200 enrolled
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Phase 3 Recruiting
120 enrolled
OPTIMAS
Phase 2 Recruiting
160 enrolled
STAMPEDE2
Phase 3 Recruiting
3,360 enrolled
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Phase NA Recruiting
116 enrolled
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Phase 2 Recruiting
96 enrolled
APPROACH
Phase NA Recruiting
566 enrolled
SPRINTR-REAL
Recruiting
5,500 enrolled
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
Phase NA Recruiting
28 enrolled
PEACE 7
Phase 3 Recruiting
700 enrolled
OCEAN
Phase 2 Recruiting
34 enrolled
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Phase 2 Recruiting
57 enrolled
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Phase 2 Recruiting
144 enrolled
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Phase 2/3 Recruiting
120 enrolled
KNIGHTS
Phase 2 Recruiting
88 enrolled
HypoElect
Phase 2 Recruiting
30 enrolled
Lead4Care
Recruiting
1,400 enrolled
RELAX
Phase 2 Recruiting
206 enrolled
HypoPro
Phase 2 Recruiting
30 enrolled
PEACE8
Phase 3 Recruiting
336 enrolled
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Phase 3 Recruiting
500 enrolled
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer
Phase NA Recruiting
130 enrolled
DIRECT
Phase 2 Recruiting
132 enrolled
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Phase 3 Recruiting
300 enrolled
SPARKLE
Phase 3 Recruiting
873 enrolled
Prostate005
Phase 2 Recruiting
60 enrolled
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2 Recruiting
102 enrolled
DEFINE
Phase 2 Recruiting
54 enrolled
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Phase 2 Recruiting
96 enrolled